Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing05:17

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

353
This protocol describes an automated, ISO15189-accredited next-generation sequencing workflow for detecting targetable genomic alterations in non-small cell lung cancer (NSCLC) formalin-fixed paraffin-embedded...
353
Manufacturing Chimeric Antigen Receptor (CAR) T Cells for Adoptive Immunotherapy06:51

Manufacturing Chimeric Antigen Receptor (CAR) T Cells for Adoptive Immunotherapy

15.9K
We describe an approach to reliably generate chimeric antigen receptor (CAR) T cells and test their differentiation and function in vitro and in...
15.9K
Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy08:40

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

18.6K
The most commonly used method for generating large numbers of autologous dendritic cells (DCs) for use in tumor immunotherapy is described. The method uses IL-4 and GM-CSF to differentiate DCs from monocytes. The immature DCs are stimulated to mature and then loaded with antigens before they are injected back into the...
18.6K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Tumor Immunotherapy01:27

Tumor Immunotherapy

1.8K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.8K
An Assay for Analyzing Test β-Glucan as an Immunotherapy Strategy against Brain Cancer Cells02:25

An Assay for Analyzing Test β-Glucan as an Immunotherapy Strategy against Brain Cancer Cells

443
This video demonstrates an in vitro assay utilizing β-glucans to activate microglial cells for the production of superoxide radicals, a reactive oxygen species. In brain cancer cells, the generated reactive oxidants actively suppress tumor cell proliferation and induce cell...
443

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Engineering CAR T Cells for Hepatocellular Carcinoma Recurrence after Liver Transplantation.

bioRxiv : the preprint server for biology·2026
Same author

Development of novel GPC2-directed radiotheranostics and CAR T cell therapy for neuroblastoma.

Molecular therapy : the journal of the American Society of Gene Therapy·2026
Same author

Prognostic Significance of Inflammatory, Cellular, and Tumor-Specific Biomarkers in Patients With Pleural and Peritoneal Mesothelioma.

Clinical lung cancer·2026
Same author

Allogeneic CRISPR-Engineered CAR-T Cells Drive Potent Antitumor Activity in Solid Tumors.

bioRxiv : the preprint server for biology·2026
Same author

Engineering functionality-optimized fully human B7-H3 CAR T cells for enhanced solid tumor therapy.

Cell reports. Medicine·2026
Same author

Enteroviral epitope mimicry enables NK cell-mediated targeting of ASPH in hepatocellular carcinoma.

bioRxiv : the preprint server for biology·2026

Related Experiment Video

Updated: Jan 19, 2026

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
05:17

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Published on: October 10, 2025

353

Mesothelin targeted cancer immunotherapy.

Raffit Hassan1, Mitchell Ho

  • 1Solid Tumor Immunotherapy Section, Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892-4264, USA. hassanr@mail.nih.gov

European Journal of Cancer (Oxford, England : 1990)
|October 20, 2007
PubMed
Summary

Mesothelin is a cancer target found on many tumors. Therapies targeting mesothelin, including immunotoxins and antibodies, are in clinical trials for various cancers.

Area of Science:

  • Oncology
  • Immunology

Background:

  • Mesothelin is a tumor antigen highly expressed in cancers like mesothelioma, pancreatic, ovarian, and lung adenocarcinoma.
  • Its normal function is unclear, but it may be involved in ovarian cancer spread by binding CA-125.
  • Limited expression in normal tissues makes mesothelin a promising target for cancer therapies.

Purpose of the Study:

  • To review the potential of mesothelin as a cancer therapeutic target.
  • To discuss current clinical evaluations of mesothelin-targeted agents.

Main Methods:

  • Review of existing literature on mesothelin.
  • Summary of ongoing clinical trials for mesothelin-targeted therapies.

Main Results:

  • Three novel mesothelin-targeted agents are in clinical evaluation: SS1P (immunotoxin), MORAb-009 (monoclonal antibody), and CRS-207 (Listeria vector).

More Related Videos

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

15.9K
Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy
08:40

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

Published on: August 1, 2013

18.6K

Related Experiment Videos

Last Updated: Jan 19, 2026

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
05:17

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Published on: October 10, 2025

353
Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

15.9K
Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy
08:40

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

Published on: August 1, 2013

18.6K

Conclusions:

  • Mesothelin's restricted expression in normal tissues and high prevalence in cancers support its utility as a therapeutic target.
  • Ongoing clinical trials are crucial for determining the effectiveness of mesothelin-targeted agents in cancer treatment.